<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>pembrolizumab phase 3 trial &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/pembrolizumab-phase-3-trial/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 20 Oct 2025 07:24:50 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>pembrolizumab phase 3 trial &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>Post-Surgery Immunotherapy Shows Promise in Treating Rare, Aggressive Skin Cancer</title>
		<link>https://bioengineer.org/post-surgery-immunotherapy-shows-promise-in-treating-rare-aggressive-skin-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Mon, 20 Oct 2025 07:24:18 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[adjuvant immunotherapy in oncology]]></category>
		<category><![CDATA[Merkel cell carcinoma immunotherapy]]></category>
		<category><![CDATA[PD-1 inhibitor metastasis prevention]]></category>
		<category><![CDATA[pembrolizumab phase 3 trial]]></category>
		<category><![CDATA[rare skin cancer treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/post-surgery-immunotherapy-shows-promise-in-treating-rare-aggressive-skin-cancer/</guid>

					<description><![CDATA[A groundbreaking phase 3 clinical trial conducted by researchers at NYU Langone Health and its Perlmutter Cancer Center has delivered promising results in the fight against Merkel cell carcinoma (MCC), a rare and aggressive skin cancer known for its rapid progression and poor survival rates. The study, which marks the largest clinical effort to date [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">283580</post-id>	</item>
	</channel>
</rss>
